EM
MCID: ERY003
MIFTS: 63

Erythema Multiforme (EM)

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme

MalaCards integrated aliases for Erythema Multiforme:

Name: Erythema Multiforme 12 77 54 38 56 45 15 17 74
Erythema Polymorphe, Erythema Multiforme Type 54
Dermatostomatitis, Erythema Multiforme Type 54
Herpes Iris, Erythema Multiforme Type 54
Febrile Mucocutaneous Syndrome 54
Erythema Multiforme Bullosum 54
Stevens-Johnson Syndrome 74
Em 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050185
KEGG 38 H01695
MeSH 45 D004892
ICD10 34 L51

Summaries for Erythema Multiforme

NIH Rare Diseases : 54 Erythema multiforme (EM) refers to a group of hypersensitivity disorders characterized by symmetric red, patchy lesions, primarily on the arms and legs. The cause is unknown, but EM frequently occurs in association with herpes simplex virus, suggesting an immunologic process initiated by the virus. In half of the cases, the triggering agents appear to be medications, including anticonvulsants, sulfonamides, nonsteroidal anti-inflammatory drugs, and other antibiotics. In addition, some cases appear to be associated with infectious organisms such as Mycoplasma pneumoniae and many viral agents. Erythema multiforme is the mildest of three skin disorders that are often discussed in relation to each other. It is generally the mildest of the three. More severe is Stevens-Johnson syndrome. The most severe of the three is toxic epidermal necrolysis (TEN).

MalaCards based summary : Erythema Multiforme, also known as erythema polymorphe, erythema multiforme type, is related to severe cutaneous adverse reaction and pulmonary fibrosis, idiopathic. An important gene associated with Erythema Multiforme is DSP (Desmoplakin), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Sirolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and prostate, and related phenotypes are Decreased hepcidin::fluc mRNA expression and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A skin disease that is a type of allergic reaction located in skin, which occurs in response to medications, infections, or illness.

Wikipedia : 77 Erythema multiforme (EM) is a skin condition of unknown cause; it is a type of erythema possibly... more...

Related Diseases for Erythema Multiforme

Diseases related to Erythema Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 severe cutaneous adverse reaction 31.7 FASLG GZMB HSPG2 TNF
2 pulmonary fibrosis, idiopathic 31.2 CCL17 CXCR3 DSP FASLG IFNG TNF
3 fixed drug eruption 30.6 IFNG IL2
4 contact dermatitis 30.5 CCL17 CXCR3 ICAM1 IFNG TNF
5 colitis 30.4 IFNG IL2 TNF
6 human immunodeficiency virus infectious disease 30.4 IFNG IL2 TNF
7 chronic graft versus host disease 30.4 IFNG TNF
8 ulcerative colitis 30.4 IFNG IL2 TNF
9 stevens-johnson syndrome/toxic epidermal necrolysis 30.3 CCL17 CXCR3 IFNG IL2
10 variola major 30.2 IFNG IL2
11 smallpox 30.2 IFNG IL2 TNF
12 annular erythema 30.1 HSPG2 ICAM1
13 myocarditis 30.1 DSP ICAM1 TNF
14 autoimmune disease 30.0 IFNG IL2 TNF
15 allergic contact dermatitis 30.0 CCL17 CXCR3 ICAM1 IFNG TNF
16 hematopoietic stem cell transplantation 30.0 IFNG IL2 TNF
17 conjunctivitis 30.0 ICAM1 IFNG IL2
18 mumps 30.0 IFNG IL2 TNF
19 poliomyelitis 30.0 ICAM1 IFNG TNF
20 lymphopenia 29.9 FASLG IFNG IL2
21 orofacial granulomatosis 29.8 CXCR3 IFNG TNF
22 graft-versus-host disease 29.8 FASLG GZMB IFNG IL2 TNF
23 hemophagocytic lymphohistiocytosis 29.7 GZMB IFNG TNF
24 lichen planus 29.6 CXCR3 GZMB ICAM1 IFNG TNF
25 cutaneous lupus erythematosus 29.6 CXCR3 GZMB ICAM1 TNF
26 keratoconjunctivitis 29.6 CCL17 ICAM1 IFNG IL2 TNF
27 rheumatoid arthritis 29.6 ICAM1 IFNG IL2 TNF
28 mycosis fungoides 29.5 CCL17 CXCR3 GZMB IL2
29 trypanosomiasis 29.5 ICAM1 IFNG IL2 TNF
30 acute graft versus host disease 29.4 FASLG GZMB IFNG IL2 TNF
31 systemic lupus erythematosus 29.4 CXCR3 FASLG ICAM1 IFNG IL2 TNF
32 dermatitis, atopic 29.3 CCL17 ICAM1 IFNG IL2 TNF
33 lymphadenitis 29.2 CXCR3 FASLG ICAM1 IFNG TNF
34 multiple sclerosis 29.0 CXCR3 ICAM1 IFNG IL2 TNF
35 alopecia areata 28.8 FASLG GZMB ICAM1 IFNG IL2 TNF
36 malaria 28.7 CXCR3 FASLG ICAM1 IFNG IL2 TNF
37 erythema multiforme major 12.6
38 eosinophilia-myalgia syndrome 12.2
39 epileptic encephalopathy, early infantile, 3 11.4
40 epileptic encephalopathy, early infantile, 4 11.4
41 erythromelalgia 11.3
42 pseudomembranous conjunctivitis 11.2
43 pulmonary embolism 11.2
44 encephalopathy, ethylmalonic 11.1
45 alpha-1-antitrypsin deficiency 11.0
46 idiopathic hemiconvulsion-hemiplegia syndrome 11.0
47 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.9
48 dermatitis 10.8
49 herpes simplex 10.8
50 lupus erythematosus 10.6

Comorbidity relations with Erythema Multiforme via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Erythema Multiforme:



Diseases related to Erythema Multiforme

Symptoms & Phenotypes for Erythema Multiforme

GenomeRNAi Phenotypes related to Erythema Multiforme according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased hepcidin::fluc mRNA expression GR00253-A 9.43 ATF3 CCL17 DSP FASLG GZMB HSPG2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 GZMB ICAM1 IL2 TNF
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 FASLG GZMB ICAM1 IL2 TNF

MGI Mouse Phenotypes related to Erythema Multiforme:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 CCL17 CXCR3 DSP FASLG HSPG2 ICAM1
2 cardiovascular system MP:0005385 10.06 CXCR3 DSP FASLG HSPG2 ICAM1 IFNG
3 hematopoietic system MP:0005397 10.02 ATF3 CCL17 CXCR3 FASLG HSPG2 ICAM1
4 immune system MP:0005387 9.97 ATF3 CCL17 CXCR3 FASLG HSPG2 ICAM1
5 digestive/alimentary MP:0005381 9.95 DSP FASLG HSPG2 ICAM1 IFNG IL2
6 integument MP:0010771 9.8 ATF3 DSP FASLG HSPG2 ICAM1 IFNG
7 neoplasm MP:0002006 9.7 ATF3 CXCR3 FASLG ICAM1 IFNG IL2
8 respiratory system MP:0005388 9.5 ATF3 CXCR3 FASLG HSPG2 IFNG IL2
9 vision/eye MP:0005391 9.1 FASLG HSPG2 ICAM1 IFNG IL2 TNF

Drugs & Therapeutics for Erythema Multiforme

Drugs for Erythema Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 881)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
4
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
5
Cilostazol Approved, Investigational Phase 4,Not Applicable 73963-72-1 2754
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177 70789204
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
8
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
9
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
10
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-48-4 104729
11
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
12
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
13
Benzoyl peroxide Approved Phase 4,Phase 3 94-36-0 7187
14
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
15
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 441203 84093 2767
16
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
17
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
18
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
19
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 38904 10339178 498142
20
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
21
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
22
Pantoprazole Approved Phase 4 102625-70-7 4679
23 Nutmeg Approved Phase 4,Phase 3,Phase 1,Not Applicable
24
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
25
Tirofiban Approved Phase 4,Not Applicable 144494-65-5 60947
26
Abciximab Approved Phase 4,Phase 2,Phase 3 143653-53-6
27
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 134523-00-5 60823
28
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492 6473866
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
30
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
31
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
32
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
33
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
34
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
35
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
36
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
37
Desonide Approved, Investigational Phase 4,Phase 3 638-94-8 5311066
38
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
39
Lenvatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 417716-92-8
40
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
41
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
42
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
43
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
44
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
45
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
46
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2 2921-57-5
47
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 302-25-0
48
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
49
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 25122-46-7, 25122-41-2 32798 5311051
50
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 378-44-9 9782

Interventional clinical trials:

(show top 50) (show all 4410)
# Name Status NCT ID Phase Drugs
1 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
2 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Unknown status NCT02563535 Phase 4
3 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
4 Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World Unknown status NCT00768846 Phase 4
5 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
6 CYPRESS - CYPHER for Evaluating Sustained Safety Unknown status NCT00954707 Phase 4 Clopidogrel & Aspirin, Prasugrel & Aspirin;Placebo & Aspirin
7 Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry) Unknown status NCT01605721 Phase 4
8 Comparison of Biomatrix and Orsiro Drug Eluting Stent Unknown status NCT02299011 Phase 4 Biomatrix drug eluting stent
9 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
10 Small Coronary Artery Treated by TAXUS Liberté Registry in Japan Unknown status NCT00955214 Phase 4
11 Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study Unknown status NCT00546845 Phase 4
12 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
13 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM) Unknown status NCT02044250 Phase 4 Clopidogrel;Aspirin
14 Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions Unknown status NCT01969630 Phase 4
15 Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary Arteries Unknown status NCT01903902 Phase 4
16 Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents Unknown status NCT01068106 Phase 4
17 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
18 Platelet Function Assessment for Atherothrombotic Patients Unknown status NCT00513149 Phase 4 Clopidogrel
19 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
20 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease Unknown status NCT01653600 Phase 4
21 BIfurcation Optimal Treatment Strategy With LYMus Eluting Dedicated Bifurcation Versus Convention Stent Randomized Study Unknown status NCT01430364 Phase 4
22 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4
23 Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions Unknown status NCT01278186 Phase 4
24 Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis Unknown status NCT00152308 Phase 4
25 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
26 To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study Unknown status NCT00870038 Phase 4
27 The 001-DIOR Multicenter Registry Unknown status NCT01375465 Phase 4
28 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
29 Local Thrombolytics Before Thrombectomy in STEMI Unknown status NCT01568931 Phase 4 Urokinase;Saline
30 Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ Unknown status NCT00914420 Phase 4
31 Impact of Intravascular Ultrasound(IVUS)-Guided Chronic Total Occlusion Intervention With Drug-eluting Stents Unknown status NCT01563952 Phase 4
32 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
33 Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
34 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
35 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
36 Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent Unknown status NCT01233453 Phase 4
37 A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions Unknown status NCT00825773 Phase 4
38 Treatment of Bifurcated Coronary Lesions With Cypher™-Stent Unknown status NCT00288535 Phase 4
39 Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI Unknown status NCT00229515 Phase 4
40 GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions Unknown status NCT00220558 Phase 4
41 Anti-Restenosis After AMI by Erythropoietin Unknown status NCT00423020 Phase 4 Erythropoietin
42 Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
43 Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) - Unknown status NCT01093300 Phase 4
44 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
45 Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction Unknown status NCT01156662 Phase 4
46 Comparison of Strut Coverage With OPTIMAX Versus SYNERGY Stents Unknown status NCT02464397 Phase 4
47 Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent: A Optical Coherent Tomography Study Unknown status NCT01925027 Phase 4
48 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
49 The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients Completed NCT03848871 Phase 4 Enstilar
50 Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus Withdrawn NCT01293773 Phase 4

Search NIH Clinical Center for Erythema Multiforme

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: erythema multiforme

Genetic Tests for Erythema Multiforme

Anatomical Context for Erythema Multiforme

The Foundational Model of Anatomy Ontology organs/tissues related to Erythema Multiforme:

20
Skin

MalaCards organs/tissues related to Erythema Multiforme:

42
Breast, Prostate, Brain, Skin, Kidney, Thyroid, T Cells

Publications for Erythema Multiforme

Articles related to Erythema Multiforme:

(show top 50) (show all 1256)
# Title Authors Year
1
Dietary supplement product composed of natural ingredients as a suspected cause of erythema multiforme: A case report and identification for the confident false positivity of lymphocyte transformation test. ( 30623481 )
2019
2
Interventions for erythema multiforme: a systematic review. ( 30680804 )
2019
3
ERYTHEMA MULTIFORME: DIFFERENCES BETWEEN HSV-1 AND HSV-2 AND MANAGEMENT OF THE DISEASE - A CASE REPORT AND MINI REVIEW. ( 30693632 )
2019
4
Pemphigoid Gestationis Mimicking Erythema Multiforme With Mucosal Involvement. ( 30732852 )
2019
5
Recurrent orogenital erythema multiforme and vulval neutrophilic dermatosis. ( 29901227 )
2018
6
A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects. ( 29515387 )
2018
7
From HSV infection to erythema multiforme through autoimmune crossreactivity. ( 29635075 )
2018
8
Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District. ( 29483990 )
2018
9
Atypical Still disease with necrotic keratinocytes: A histologic mimicker of erythema multiforme. ( 29693054 )
2018
10
A Large Epidemiological Study Of Erythema Multiforme In France, With Emphasis On Treatment Choices. ( 29957881 )
2018
11
Erythema multiforme after orf virus infection. ( 29766553 )
2018
12
Urticaria multiforme, an "erythema multiforme" simulator. ( 29398004 )
2018
13
Tularemia-induced erythema multiforme minor in an 11-year-old girl. ( 29582465 )
2018
14
Characteristics of pediatric recurrent erythema multiforme. ( 29231254 )
2018
15
Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme. ( 29450445 )
2018
16
Pediatric Lip Adhesion Following Bullous Erythema Multiforme and Review of Similar Oral Complications. ( 29463113 )
2018
17
Reactive perforating leprosy, erythema multiforme-like reactions, sweet's syndrome-like reactions as atypical clinical manifestations of Type 2 leprosy reaction. ( 29516895 )
2018
18
Current Perspectives on Erythema Multiforme. ( 29352387 )
2018
19
Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. ( 29387340 )
2018
20
Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. ( 29559400 )
2018
21
Drug-induced oral erythema multiforme: A diagnostic challenge. ( 29363636 )
2018
22
Erythema Multiforme Major After Immunotherapy With Diphenylcyclopropenone for Alopecia Areata. ( 30346328 )
2018
23
Hemophagocytic lymphohistiocytosis presenting with annular erythema multiforme-like eruptions in a patient with angioimmunoblastic T cell lymphoma: A case report. ( 30186440 )
2018
24
Golimumab-associated persistent erythema multiforme in a patient with ulcerative colitis in full remission. ( 30142713 )
2018
25
Erythema multiforme-like contact dermatitis caused by herbal medicine. ( 30411366 )
2018
26
Orofacial granulomatosis and erythema multiforme in an adolescent with Crohn's disease. ( 30024055 )
2018
27
Erythema multiforme major induced by exotic wood. ( 29987843 )
2018
28
The effect of levamisole in the treatment of recalcitrant recurrent erythema multiforme major: An observational study. ( 30143369 )
2018
29
Erythema multiforme major with swollen lips and crusted erosions. ( 30152391 )
2018
30
Case of Erythema Multiforme Drug Eruption Induced by Ledipasvir/Sofosbuvir. ( 30188425 )
2018
31
Histopathology of Hand-Foot-Mouth Disease in Adults and Criteria for Differentiation From Erythema Multiforme. ( 30211734 )
2018
32
Severe hand-foot skin reaction and erythema multiforme-like lesions due to sorafenib. ( 30224351 )
2018
33
A Rare Case Report of Giant Cell Tumor of the Sphenoid Bone in a Patient Who Developed "Erythema Multiforme Associated with Phenytoin and Cranial Radiation Therapy Syndrome". ( 30283572 )
2018
34
Postpartum eruption of enoxaparin-induced erythema multiforme. ( 30349708 )
2018
35
Deflazacort-Induced Erythema Multiforme Exudativum Successfully Treated With a Single Dose of Etanercept. ( 30350788 )
2018
36
Polymorphous Light Eruption Mimicking Erythema Multiforme. ( 30373707 )
2018
37
Case of Erythema Multiforme Drug Eruption Induced by Ledipasvir/Sofosbuvir: Erratum. ( 30398997 )
2018
38
Herpes-Associated Erythema Multiforme. ( 30476966 )
2018
39
Secondary syphilis presenting as erythema multiforme in a HIV-positive homosexual man: a case report and literature review. ( 30482099 )
2018
40
Variants of Erythema Multiforme: A Case Report and Literature Review. ( 30564538 )
2018
41
Erythema multiforme as a reaction to imiquimod 5% cream. ( 28329504 )
2017
42
Contact dermatitis caused by Geranium robertianum with erythema multiforme-like reaction. ( 29164698 )
2017
43
Erythema multiforme following pneumococcal vaccination. ( 28352933 )
2017
44
Autoimmune progesterone dermatitis manifesting as mucosal erythema multiforme in the setting of HIV infection. ( 28050592 )
2017
45
Risperidone-induced Erythema Multiforme Minor. ( 29284818 )
2017
46
Erythema multiforme-like reaction resulting from vitamin K<sub>1</sub>oxide (phytomenadione epoxide). ( 29063687 )
2017
47
Erythema multiforme-like lesions in primary cutaneous aggressive cytotoxic epidermotropic CD8+ T-cell lymphoma: A diagnostic and therapeutic challenge. ( 28644551 )
2017
48
Erythema multiforme induced by alendronate sodium in a geriatric patient: A case report and review of the literature. ( 28828163 )
2017
49
New Presentation of Autoimmune Hepatitis with Erythema Multiforme. ( 29059460 )
2017
50
Dermoscopy of erythema multiforme. ( 28217488 )
2017

Variations for Erythema Multiforme

Expression for Erythema Multiforme

Search GEO for disease gene expression data for Erythema Multiforme.

Pathways for Erythema Multiforme

Pathways related to Erythema Multiforme according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 ATF3 CCL17 CXCR3 DSP FASLG HSPG2
2
Show member pathways
13.16 CCL17 CXCR3 FASLG IL2 TNF
3
Show member pathways
12.67 FASLG GZMB ICAM1 IFNG IL2 TNF
4
Show member pathways
12.46 FASLG ICAM1 IFNG IL2 TNF
5 12.41 FASLG GZMB IFNG IL2 TNF
6 12.26 ATF3 ICAM1 IL2 TNF
7
Show member pathways
12.23 ICAM1 IFNG IL2 TNF
8
Show member pathways
12.21 CCL17 IFNG TNF
9
Show member pathways
12.21 ATF3 HSPG2 IFNG TNF
10 12.18 FASLG HSPG2 TNF
11 12.13 FASLG GZMB TNF
12
Show member pathways
12.11 FASLG GZMB ICAM1 IFNG IL2 TNF
13
Show member pathways
12.1 CCL17 CXCR3 HSPG2 ICAM1
14
Show member pathways
12.09 CCL17 IL2 TNF
15
Show member pathways
12.09 FASLG IFNG TNF
16
Show member pathways
12.07 FASLG IFNG TNF
17 11.98 ICAM1 IFNG TNF
18
Show member pathways
11.96 CCL17 ICAM1 IFNG IL2
19
Show member pathways
11.95 IFNG IL2 TNF
20
Show member pathways
11.93 HSPG2 IFNG TNF
21 11.89 IFNG IL2 TNF
22 11.89 ICAM1 IFNG IL2 TNF
23 11.88 FASLG ICAM1 TNF
24
Show member pathways
11.83 FASLG GZMB IFNG IL2
25 11.77 ICAM1 IFNG TNF
26 11.72 ICAM1 IFNG IL2
27 11.67 IFNG IL2 TNF
28
Show member pathways
11.61 FASLG IFNG IL2 TNF
29 11.56 CCL17 IFNG IL2 TNF
30
Show member pathways
11.47 ICAM1 IFNG IL2 TNF
31 11.46 ICAM1 IFNG TNF
32 11.44 IFNG IL2 TNF
33 11.41 CCL17 IFNG IL2
34 11.39 FASLG IFNG TNF
35 11.36 FASLG ICAM1 IFNG
36 11.33 FASLG IFNG IL2 TNF
37 11.26 CXCR3 GZMB IFNG IL2 TNF
38 11.22 IFNG IL2
39 11.21 IFNG TNF
40 11.16 IFNG IL2 TNF
41 11.14 IFNG IL2
42 11.13 FASLG ICAM1 IFNG TNF
43 11.1 IFNG IL2
44 11.08 ICAM1 IFNG
45 11.08 CCL17 FASLG IL2 TNF
46 10.97 ATF3 IFNG
47 10.91 CCL17 FASLG HSPG2 IL2 TNF
48 10.87 ICAM1 TNF
49
Show member pathways
10.81 FASLG GZMB IFNG IL2 TNF

GO Terms for Erythema Multiforme

Cellular components related to Erythema Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.56 CXCR3 FASLG ICAM1 TNF
2 external side of plasma membrane GO:0009897 9.26 CXCR3 FASLG ICAM1 TNF
3 extracellular space GO:0005615 9.17 CCL17 FASLG HSPG2 ICAM1 IFNG IL2
4 immunological synapse GO:0001772 9.16 GZMB ICAM1

Biological processes related to Erythema Multiforme according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.87 ATF3 FASLG IFNG IL2
2 inflammatory response GO:0006954 9.78 CCL17 CXCR3 HSPG2 TNF
3 extracellular matrix organization GO:0030198 9.76 HSPG2 ICAM1 TNF
4 cytokine-mediated signaling pathway GO:0019221 9.76 FASLG ICAM1 IL2 TNF
5 positive regulation of protein phosphorylation GO:0001934 9.73 IFNG IL2 TNF
6 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.59 FASLG ICAM1
7 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.58 FASLG TNF
8 negative regulation of myoblast differentiation GO:0045662 9.55 CCL17 TNF
9 regulation of signaling receptor activity GO:0010469 9.55 CCL17 FASLG IFNG IL2 TNF
10 positive regulation of protein complex assembly GO:0031334 9.54 IFNG TNF
11 extrinsic apoptotic signaling pathway GO:0097191 9.54 FASLG IFNG TNF
12 positive regulation of osteoclast differentiation GO:0045672 9.52 IFNG TNF
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.51 IFNG TNF
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.5 ICAM1 IFNG TNF
15 regulation of regulatory T cell differentiation GO:0045589 9.49 IFNG IL2
16 necroptotic signaling pathway GO:0097527 9.43 FASLG TNF
17 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.4 ICAM1 TNF
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG TNF
19 immune response GO:0006955 9.1 CCL17 CXCR3 FASLG IFNG IL2 TNF
20 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 IFNG TNF

Molecular functions related to Erythema Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL17 FASLG IFNG IL2 TNF
2 tumor necrosis factor receptor binding GO:0005164 8.96 FASLG TNF

Sources for Erythema Multiforme

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....